A new Phase 1 signal emerged for an engineered NK/T-cell engagement strategy in advanced non-small cell lung cancer. In nine patients, Rapport’s investigational NK510 program—described as TIGIT-disrupted NK510—combined with PD-1 blockade showed preliminary safety without observed dose-limiting toxicities. The study reported highly uncertain early efficacy estimates, with the main near-term readout focused on tolerability in a heavily pretreated population typical of early-phase oncology trials. Trial activity suggests the platform may support further dose-escalation and expansion cohorts. For drug developers, the results matter as a reference point for how TIGIT pathway disruption can be combined with checkpoint therapy in solid tumors—an area where early clinical outcomes will heavily influence investment and partnering decisions.